# US 2022/0033495 A1 · Antibody for pure isolation of vascular endothelial cells and preparation method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033495 A1
- Document ID: US20220033495A1
- Status: Published application
- Kind: A1
- Application number: 17/270,231
- Filed: 2019-08-20
- Published: 2022-02-03
- Earliest claimed: 2018-08-20
- Assignees: Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Young Sup YOON; Shin Jeong LEE; Dong Chan SON
- Web page: https://patentgrep.com/patent/US20220033495A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/069: {Vascular Endothelial cells}
- G01N 33/56966: {Animal cells}
- G01N 35/00: Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2506/45: from artificially induced pluripotent stem cells
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2800/7014: (Neo)vascularisation - Angiogenesis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present specification provides an antibody for pure isolation of vascular endothelial cells and a preparation method thereof, the antibody comprising: a heavy chain variable domain and a light chain variable domain which specifically bind to an extracellular matrix domain of PECAM1 having an amino acid sequence of SEQ ID NO: 1; or a heavy chain variable domain and a light chain variable domain which specifically bind to an extracellular matrix domain of CDH5 having an amino acid sequence of SEQ ID NO: 2.

## Claims

### Claim 1

An antibody for purifying a vascular endothelial cell, the antibody containing a heavy-chain variable domain and a light-chain variable domain specifically binding to an extracellular matrix domain of PECAM1 having an amino acid sequence represented by SEQ ID NO: 1 or CDH5 having an amino acid sequence represented by SEQ ID NO: 2.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody includes a monoclonal antibody specifically binding to the extracellular matrix domain of PECAM1 or the extracellular matrix domain of CDH5.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody further includes a heavy-chain invariable domain and a magnetic particle,
wherein the magnetic particle is attached to the heavy-chain invariable domain of the antibody.

### Claim 4

A method for producing an antibody for purifying a vascular endothelial cell, the method comprising:
injecting a protein containing an extracellular matrix domain of PECAM1 having an amino acid sequence represented by SEQ ID NO: 1 into an antibody producing subject so as to produce an antibody against the PECAM1;
determining a positive clone reacting with an antigen of the PECAM1 from the antibody producing subject; and
separating the antibody against the PECAM1 from the positive clone.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method further includes, prior to the injection of the protein into the antibody producing subject:
preparing a recombinant plasmid vector containing a base sequence expressing the extracellular matrix domain of the PECAM1;
transfecting the recombinant plasmid vector into a host cell; and
obtaining the protein containing the extracellular matrix domain of the PECAM1.

### Claim 6 (depends on 4)

The method of claim 4, wherein the determining of a positive clone includes:
separating a plurality of B lymphocytes from the antibody producing subject;
fusing the plurality of B lymphocytes with myeloma cells respectively to produce fused cells;
culturing the plurality of the fused cells respectively to form a clone; and
determining the positive clone to react with the antigen of the PECAM1 from the formed clone,
wherein separating the antibody includes purifying a monoclonal antibody against the PECAM1 from the positive clone.

### Claim 7 (depends on 4)

The method of claim 4, wherein a concentration of the separated antibodies against the PECAM1 is at least 3.5 mg/ml.

### Claim 8 (depends on 4)

The method of claim 4, wherein the separated antibodies against the PECAM1 maintain a specificity and a binding affinity to the extracellular matrix domain of the PECAM1 at a concentration of 0.004 mg/ml or lower of the antibodies.

### Claim 9

A method for producing an antibody for purifying a vascular endothelial cell, the method comprising:
injecting a protein containing an extracellular matrix domain of CDH5 having an amino acid sequence represented by SEQ ID NO: 2 into an antibody producing subject so as to produce an antibody against the CDH5;
determining a positive clone reacting with an antigen of the CDH5 from the antibody producing subject; and
separating the antibody against the CDH5 from the positive clone.

### Claim 10 (depends on 9)

The method of claim 9, wherein the method further includes, prior to the injection of the protein into the antibody producing subject:
preparing a recombinant plasmid vector containing a base sequence expressing the extracellular matrix domain of CDH5;
transfecting the recombinant plasmid vector to a host cell; and
obtaining the protein containing the extracellular matrix domain of CDH5.

### Claim 11 (depends on 9)

The method of claim 9, wherein the determining of the positive clone includes:
separating a plurality of B lymphocytes from the antibody producing subject;
fusing the plurality of B lymphocytes with myeloma cells respectively to produce fused cells;
culturing the plurality of the fused cells respectively to form a clone; and
determining the positive clone to react with the antigen of CDH5 from the formed clone,
wherein separating the antibody includes purifying a monoclonal antibody against the CDH5 from the positive clone.

### Claim 12 (depends on 9)

The method of claim 9, wherein a concentration of the separated antibodies against the CDH5 is at least 3.5 mg/ml.

### Claim 13 (depends on 9)

The method of claim 9, wherein the separated antibodies against the CDH5 maintain a specificity and a binding affinity to the extracellular matrix domain of the CDH5 at a concentration of 0.004 mg/ml or lower of the antibodies.

### Claim 14 (depends on 1, 2, 3)

A method for purifying a vascular endothelial cell, the method comprising:
differentiating an endothelial cell from a stem cell to obtain a cell cluster containing a vascular endothelial cell and an endothelial cell different from the vascular endothelial cell;
applying the antibody of one of claims 1 to 3 to the cell cluster, such that a protein of PECMA1 or a protein of CDH5 present on a surface of the vascular endothelial cell immuno-responses to the antibody for purifying the vascular endothelial cell; and
sorting a cell exhibiting fluorescence in an immunofluorescence staining process due to the immuno-response as a vascular endothelial cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein the stem cell includes a human pluripotent stem cell or a human induced pluripotent stem cell.

### Claim 16 (depends on 14)

The method of claim 14, wherein the differentiating includes culturing the stem cell in a DLL4-treated medium to differentiate the endothelial cell.

### Claim 17 (depends on 14)

The method of claim 14, wherein the antibody for purifying the vascular endothelial cell further contains a magnetic particle,
wherein the sorting includes:
permeating the antibody-treated cell cluster into a column, wherein the column receives a metallic particle therein, and a magnetic force is externally applied to the column; and
sorting a cell bound to the metallic particle located inside the column as the vascular endothelial cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the sorting includes sorting the vascular endothelial cell by blocking the magnetic force externally applied to the column.

### Claim 19 (depends on 1, 2, 3)

A kit for purifying a vascular endothelial cell, the kit comprising the antibody of one of claims 1 to 3.
